Commercial Payer PA Requirements for Biologics: A Side-by-Side Comparison

One of the most time-consuming parts of biologic prior authorization isn't the actual submission — it's the research. Every major commercial payer has different step therapy requirements, different documentation checklists, different preferred agents, and different turnaround timelines. A submission that would sail through Aetna might get kicked back by Cigna for a missing data point.

This post is meant to be a practical reference. Bookmark it. It covers the four major commercial payers — UnitedHealthcare, Aetna, Cigna, and BCBS — across the biologics most commonly submitted for rheumatology, dermatology, and gastroenterology indications.

Note: Payer requirements change. Verify current criteria through each payer's portal or clinical guidelines before submitting. This comparison reflects general patterns as of early 2026.

UnitedHealthcare

UnitedHealthcare uses its own clinical coverage policies, published on the UHC Provider Portal. These are drug-specific and indication-specific — not a single biologic policy, but separate documents for each agent and condition.

Step Therapy

UHC requires documented failure of conventional DMARDs before approving TNF inhibitors for RA. For IL-17 and IL-23 inhibitors in psoriasis and PsA, UHC typically requires prior failure of at least one conventional systemic agent (methotrexate or cyclosporine). Adalimumab biosimilars are preferred over branded Humira in most UHC plans.

Required Documentation

• Diagnosis codes with supporting clinical rationale
• Disease activity scores (DAS28, PASI, CDAI, or equivalent)
• Documented trial and failure of required prior therapies, including dates and reasons for discontinuation
• Lab values (baseline TB test, hepatitis screening)
• Prescriber NPI and specialty

Turnaround Times

Standard: 3–5 business days. Urgent/expedited: 24–72 hours with documented clinical urgency. UHC processes most biologic PAs through the Provider Portal or via CoverMyMeds integration.

Preferred Biologics / Biosimilars

UHC has moved aggressively toward biosimilar-first policies. Adalimumab biosimilars (Hadlima, Hyrimoz, Cyltezo) are tier-preferred in most commercial plans. Infliximab biosimilars similarly preferred over Remicade. Etanercept biosimilars preferred over branded Enbrel where available.

Appeals

UHC allows first-level appeals within 60 days of denial. Peer-to-peer review requests should be made within 14 days of denial notice. Second-level appeals and external review are available for continued denials.

Aetna

Aetna publishes Medical Clinical Policy Bulletins (MCPBs) that govern biologic coverage. These are publicly available and detailed — probably the most transparent of the four major payers in terms of published criteria.

Step Therapy

Aetna's step therapy for RA biologics requires 3–6 months of conventional DMARD therapy (typically methotrexate at adequate dose) with documented inadequate response. For psoriasis, prior failure of at least one of the following: methotrexate, cyclosporine, or PUVA/UVB phototherapy. Aetna generally aligns with ACR and AAD treatment guidelines, which makes their criteria somewhat predictable if you know the guidelines.

Required Documentation

• Specific diagnosis code matching the requested indication
• Quantified disease activity (provider-documented, not self-reported)
• Prior therapy documentation: agent name, dose, duration, and reason for discontinuation
• Baseline safety labs (TB, hepatitis B and C, CBC)
• Statement that the requested biologic is medically necessary and preferred over alternatives

Turnaround Times

Standard: 3 business days. Urgent: 1 business day with supporting rationale. Aetna uses Availity and NaviMedix for portal submissions.

Preferred Biologics / Biosimilars

Aetna's formulary varies by employer group plan. Large group commercial plans often have biosimilar preference built in. For IBD indications, infliximab biosimilars are frequently preferred over Remicade. For RA, adalimumab biosimilars are gaining preference position over branded Humira.

Appeals

Aetna allows appeals within 180 days of denial — the longest window of the four major payers. Peer-to-peer is available within 30 days of denial. External independent review is available after internal appeal exhaustion.

Cigna

Cigna uses coverage policies published through its provider portal and coverage policy library. Cigna's biologic policies tend to be more restrictive on step therapy documentation — they want specifics, not summaries.

Step Therapy

Cigna requires documented failure of first-line agents that often must include specific dose information and treatment duration. For RA: methotrexate failure or contraindication required before most TNF inhibitors. For plaque psoriasis: conventional systemic failure plus BSA documentation and PASI scoring. For CD/UC: conventional immunosuppressant (azathioprine or 6-MP) trial typically required before biologics.

Required Documentation

• Diagnosis confirmed by appropriate specialist (Cigna may specify rheumatologist, dermatologist, or gastroenterologist)
• Quantified disease severity metrics, not just clinical description
• Complete prior therapy history with exact dates (month/year), doses, and specific failure documentation
• Safety labs within 6 months
• For biosimilar exceptions: clinical rationale for branded product preference

Turnaround Times

Standard: 3–5 business days. Urgent: 72 hours. Cigna processes through eviCore for many specialty drug categories — check whether the specific biologic goes through Cigna directly or through eviCore before submitting.

Preferred Biologics / Biosimilars

Cigna has one of the more aggressive biosimilar-first positions in the market. Adalimumab biosimilars are the first-line preferred agents in most Cigna commercial plans. Non-medical switching (moving a stable patient from originator to biosimilar) is a documented Cigna practice that providers should be prepared for.

Appeals

Cigna standard appeal: 60 days from denial. eviCore-managed denials go through eviCore's appeal process first. Peer-to-peer available within 5 business days of denial. External review available after internal exhaustion.

Blue Cross Blue Shield

BCBS is not a single payer — it's 35+ independent licensees with their own coverage policies. What applies to BCBS of Texas may not apply to BCBS of Massachusetts. That said, most licensees follow similar structural patterns, and many use AIM Specialty Health or Magellan Rx Management for specialty drug utilization management.

Step Therapy

Most BCBS plans align with specialty society guidelines (ACR, AAD, AGA). Conventional DMARD failure required for RA biologics. For psoriasis, requirements vary by licensee but generally follow AAD guidelines. The key variable is which UM vendor manages biologics for the specific BCBS plan.

Required Documentation

• Treating physician specialty and NPI
• Diagnosis documentation with ICD-10 specificity
• Disease severity assessment using validated tools (BSA, PASI, DAS28, HBI, etc.)
• Prior therapy records — BCBS plans are generally less prescriptive than Cigna on format but want the same substance
• Lab work per indication

Turnaround Times

Varies by licensee. Most follow federal/state minimum timelines: 3–5 business days standard, 24–72 hours urgent. Some licensees use AIM Specialty Health, which has its own portal and timeline. Verify which system handles the specific plan before submitting.

Preferred Biologics / Biosimilars

Biosimilar preference is increasingly common across BCBS plans but varies by licensee. Some plans have implemented biosimilar-first tiers with higher cost-sharing for originator products. Check the specific plan formulary — BCBS lacks the national uniformity of the other three payers on this dimension.

Appeals

BCBS plans are required by ACA to allow first-level internal appeals (60–180 days depending on state) and external review. Peer-to-peer availability varies by licensee. If your BCBS plan uses AIM or Magellan, the peer-to-peer goes through the vendor, not the plan directly.

Quick Reference: What Each Payer Cares About Most

The Maintenance Problem

Here's the honest challenge with a comparison like this: it's accurate today and will drift over time. Payers update their coverage policies annually — and sometimes mid-year for biosimilar additions or formulary shifts. Practices that rely on static reference sheets built 18 months ago are submitting to criteria that may no longer exist.

That's exactly the problem Luma addresses. Rather than maintaining a static database of payer requirements, Luma researches current payer-specific criteria at the time of each submission — so the documentation is built against what the plan actually requires right now, not what it required when someone last updated a spreadsheet.

For more on payer documentation strategies, visit the Luma blog.

Sources: UnitedHealthcare Prior Authorization and Notification requirements (uhcprovider.com); Aetna Medical Clinical Policy Bulletins, Biologics and Specialty Drugs (aetna.com); Cigna Coverage Policy Library, Specialty Drugs (cigna.com); BCBS Association, Prior Authorization Modernization overview (bcbs.com); American College of Rheumatology Treatment Guidelines 2021 (rheumatology.org); American Academy of Dermatology Psoriasis Treatment Guidelines (aad.org).